DE69226990T2 - Tumorantigen-spezifischer Antikörper - Google Patents

Tumorantigen-spezifischer Antikörper

Info

Publication number
DE69226990T2
DE69226990T2 DE69226990T DE69226990T DE69226990T2 DE 69226990 T2 DE69226990 T2 DE 69226990T2 DE 69226990 T DE69226990 T DE 69226990T DE 69226990 T DE69226990 T DE 69226990T DE 69226990 T2 DE69226990 T2 DE 69226990T2
Authority
DE
Germany
Prior art keywords
antibody
cell line
monoclonal antibody
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69226990T
Other languages
German (de)
English (en)
Other versions
DE69226990D1 (de
Inventor
Jan S-421 74 Vaestra Froelunda Holmgren
Peter S-752 27 Uppsala Lind
Leif S-430 41 Kullavik Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of DE69226990D1 publication Critical patent/DE69226990D1/de
Publication of DE69226990T2 publication Critical patent/DE69226990T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69226990T 1991-07-03 1992-07-03 Tumorantigen-spezifischer Antikörper Expired - Lifetime DE69226990T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (2)

Publication Number Publication Date
DE69226990D1 DE69226990D1 (de) 1998-10-22
DE69226990T2 true DE69226990T2 (de) 1999-03-25

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69226990T Expired - Lifetime DE69226990T2 (de) 1991-07-03 1992-07-03 Tumorantigen-spezifischer Antikörper

Country Status (19)

Country Link
US (1) US5552293A (cg-RX-API-DMAC10.html)
EP (1) EP0521842B1 (cg-RX-API-DMAC10.html)
JP (1) JP3194020B2 (cg-RX-API-DMAC10.html)
KR (1) KR100246681B1 (cg-RX-API-DMAC10.html)
AT (1) ATE171193T1 (cg-RX-API-DMAC10.html)
AU (2) AU658198B2 (cg-RX-API-DMAC10.html)
CA (1) CA2073124C (cg-RX-API-DMAC10.html)
DE (1) DE69226990T2 (cg-RX-API-DMAC10.html)
DK (1) DK0521842T3 (cg-RX-API-DMAC10.html)
EE (1) EE03031B1 (cg-RX-API-DMAC10.html)
ES (1) ES2124250T3 (cg-RX-API-DMAC10.html)
FI (1) FI109207B (cg-RX-API-DMAC10.html)
HU (2) HU218084B (cg-RX-API-DMAC10.html)
IE (1) IE80841B1 (cg-RX-API-DMAC10.html)
IL (1) IL102390A (cg-RX-API-DMAC10.html)
NO (1) NO315472B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ243435A (cg-RX-API-DMAC10.html)
SE (1) SE9102074D0 (cg-RX-API-DMAC10.html)
WO (2) WO1993001302A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
JP2004537976A (ja) * 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EP3411409B1 (en) 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
EP4732850A1 (en) 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
AU656906B2 (en) * 1990-07-20 1995-02-23 Active Biotech Ab Target specific antibody-superantigen conjugates and their preparation

Also Published As

Publication number Publication date
KR100246681B1 (ko) 2000-04-01
CA2073124A1 (en) 1993-01-04
SE9102074D0 (sv) 1991-07-03
NO934777L (no) 1994-02-11
WO1993001303A1 (en) 1993-01-21
ATE171193T1 (de) 1998-10-15
IL102390A (en) 1996-01-19
EP0521842A3 (cg-RX-API-DMAC10.html) 1994-01-26
IL102390A0 (en) 1993-01-14
EP0521842B1 (en) 1998-09-16
CA2073124C (en) 2007-06-19
NO934777D0 (no) 1993-12-22
EP0521842A2 (en) 1993-01-07
NO315472B1 (no) 2003-09-08
JP3194020B2 (ja) 2001-07-30
HU9400011D0 (en) 1994-05-30
FI109207B (fi) 2002-06-14
ES2124250T3 (es) 1999-02-01
HU211512A9 (en) 1995-11-28
NZ243435A (en) 1994-10-26
EE03031B1 (et) 1997-08-15
HUT71193A (en) 1995-11-28
HU218084B (hu) 2000-05-28
AU658198B2 (en) 1995-04-06
FI935970A0 (fi) 1993-12-31
DK0521842T3 (da) 1999-06-14
DE69226990D1 (de) 1998-10-22
US5552293A (en) 1996-09-03
JPH05276987A (ja) 1993-10-26
IE80841B1 (en) 1999-03-24
IE922188A1 (en) 1993-01-13
WO1993001302A1 (en) 1993-01-21
AU1942592A (en) 1993-01-07
FI935970L (fi) 1993-12-31
AU2292092A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
EP0521842B1 (en) Tumor antigen specific antibody
DE69525593T2 (de) Humanisierte und chimäre monoklonale Antikörper die den Rezeptor für epidermalen Wachstumfaktor (EGF-R) erkennen; diagnostische und therapeutische Verwendung
DE69330523T2 (de) Immunoglobuline ohne leichte ketten
DE69431602T2 (de) Monoklonale antikörper zur diagnose und behandlung von kolorektalkrebs
DE69734109T2 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
DE69133200T2 (de) Spezifisch bindende Agentien
DE69605181T2 (de) Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE69325577T2 (de) Mn-gen und protein
DE3888172T2 (de) Rekombinant-antikörper.
DE3751908T2 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
DE69530975T2 (de) Rekombinante humanisierte antikörper gegen lewis y
DE3586440T2 (de) Zur diagnose von menschlichem magen- oder brustkrebs zu verwendender monoklonaler antikoerper.
DE69808609T2 (de) Antagonistische anti-avb3 integrin antikörper
CA2210751C (en) Anti-cd6 monoclonal antibodies and their uses
DE69222956T2 (de) Kleinste erkennungseinheit eines pem-mucin-"tandem repeat"-spezifischen monoklonalen antikoerpers
AU684863B2 (en) Binding structures directed against the CA55.1 antigen
DE69331735T2 (de) Gegen das A33 Antigen gerichtete Humanisierte Antikörper
DE69029970T2 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
JP2002502621A (ja) 乳腫瘍を伴うムチンに対する特異性のある抗体、その生産方法及び使用方法
DE60214127T2 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
DE69334036T2 (de) Hybridom und humanisierter momoklonaler Anti-KC-4-Antikörper, dafür kodierende DNA und RNA, Kit und diagnostische Verfahren
DE69331942T2 (de) Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper
DE69032096T2 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
TWI894595B (zh) 抗促腎上腺皮質激素釋放激素抗體和多囊卵巢症候群
DE69133287T2 (de) An tag-72 bindende zusammengesetzte antikörper mit der humanen leichten kette der untergruppe-iv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 521842

Country of ref document: EP